Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20132790 | 1.00 | LMNA (0.45) | LMNAL3MBTL1CTSBNR1H4TDP1 | |
| SCHEMBL20128491 | 0.85 | CTSB (0.43) | CTSBSMN1; SMN2CYP2C19ALDH1A1HTT | |
| SCHEMBL20128499 | 0.85 | CTSB (0.43) | CTSBSMN1; SMN2CYP2C19ALDH1A1HTT | |
| SCHEMBL27707724 | 0.80 | L3MBTL1 (0.52) | LMNAL3MBTL1TDP1SMN1; SMN2MMP8 | |
| SCHEMBL7910564 | 0.80 | LMNA (0.42) | LMNAL3MBTL1NR1H4TDP1SMN1; SMN2 | |
| SCHEMBL900165 | 0.79 | TDP1 (0.57) | LMNAL3MBTL1TDP1SMN1; SMN2MMP8 | |
| SCHEMBL20132791 | 0.79 | HPRT1 (0.42) | LMNAL3MBTL1TDP1SMN1; SMN2CYP2C19 | |
| SCHEMBL20132829 | 0.79 | HPRT1 (0.42) | LMNAL3MBTL1TDP1SMN1; SMN2CYP2C19 | |
| SCHEMBL23620881 | 0.78 | L3MBTL1 (0.51) | LMNAL3MBTL1NR1H4TDP1SMN1; SMN2 | |
| SCHEMBL20180712 | 0.78 | L3MBTL1 (0.51) | LMNAL3MBTL1NR1H4TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040760-B2 | Pyrrolidine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-08-07 | — | — | US | disclosed |
| US-20180127364-A1 | PYRROLIDINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127364-A1 | PYRROLIDINE COMPOUND | CAT, POLI, PPOX | LMNA 4051/4885L3MBTL1 4632/4885CTSB 387/4885 |
| US-10040760-B2 | Pyrrolidine compound | CAT, POLI, PPOX | LMNA 4051/4885L3MBTL1 4632/4885CTSB 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.